Esquemas alternativos
•
Menor toxicidad y mejor tolerancia
Año
Autores
Título
Revista
Tipo
2009
Gyergyay
Decreased toxicity schedule of sunitinib in renal cell cancer: 2 weeks on/1 week off
J Clin Oncol
Abst
2013
Neri et al
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single‐center experience with 31
patients
Int J Urol
Art
2014
Atkinson et
Clinical outcomes for patients with mRCC treated with alternative sunitinib schedule
J Urol
Art
2014
Bjarnason et al
Outcomes in patients with mRCC treated with individual sunitinib therapy: correlation with dynamic microbubble ultrasound data and
review of the literature
Urol Oncol
Art
2014
Bracarda et al
Retrospective observational study administered on schedule 2/1 in patients with mRCC: The rainbow study
J Clin Oncol
Abst
2014
Cheng et al
Survival outcomes associated with different sunitinib dosing regimens in mRCC
J Clin Oncol
Abst
2014
Kondo et al
Superior tolerability of altered dosing schedule of sunitinib with 2‐weeks‐on and 1‐week‐off in patients with mRCC. Comparison to
standard dosing schedule of 4‐weeks‐on and 2‐weeks‐off
Jpn J Clin Oncol
Art
2014
Najjar et al
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity inmRCC
Eur JCancer
Art
2014
Ohzeki et al
Efficacy of traditional and alternative schedule in Japanese patients with mRCC
Int J Urol
Art
2014
Togo et al
The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of mRCC
Hinkyokika Kiyo
Art
2015
Miyake et al
Improved health‐related quality of life of patients with mRCC treated with a 2 weeks on and 1 week off schedule of sunitinib
Med Oncol
Art
